Posted by Michael Wonder on 11 Nov 2023
Highlights from the 6-9 November 2023 CHMP meeting
10 November 2023 - The EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its November 2023 meeting.
The CHMP adopted a positive opinion for Omjjara (momelotinib), for the treatment of myelofibrosis, a rare blood cancer that affects the bone marrow.
